6 active not recruiting, 5 recruiting, 4 completed, 2 terminated. 7 Phase 2, 4 Phase 1, 3 Not applicable, 2 Phase 3, 1 Phase 4.
Follow Oral Cavity Carcinoma: new trials by email Literature Review of Oral Cavity Carcinoma trials Research Report on Oral Cavity Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck Cancers Electronic Health Record Review, Fentanyl, Laryngoscopy - Head and Neck Carcinoma, Hypopharyngeal Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 58 | 2026-09-22 | 2026-10-05 |
| Thermotherapy for Head and Neck Cancer Patients Thermotherapy, Radiotherapy, Concurrent chemoradiation - Head and Neck Cancer, Oropharyngeal Carcinoma | Phase 1 | Recruiting | Erasmus Medical Center | 30 | 2026-09-01 | 2026-09-02 |
| APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma APG-157, Surgery, Radiation/Chemotherapy - Head and Neck Cancer, Head and Neck (HNSCC) | Phase 3 | Not yet recruiting | Aveta Biomics, Inc. | 826 | 2026-07-01 | 2026-07-01 |
| Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection) - Head and Neck Cancers- Squamous Cell, Head and Neck Cancer | Phase 1 | Recruiting | VLP Therapeutics | 41 | 2025-05-13 | 2026-09-21 |
| Thermotherapy for Locally Advanced Head and Neck Cancer Thermotherapy, radiotherapy - Head and Neck Cancer, Oropharyngeal Carcinoma | Phase 1 | Active not recruiting | Erasmus Medical Center | 2 | 2025-05-01 | 2026-09-02 |
| Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers Standard post-operative radiotherapy without flap sparing (current practice), Post-operative radiotherapy with flap sparing - Oral Cavity Carcinoma, Flap | Phase 3 | Recruiting | Centre Francois Baclesse | 348 | 2025-03-01 | 2026-10-27 |
| Role of Acetaldehyde in the Development of Oral Cancer Alcohol, Biospecimen Collection, Breath Test - Alcohol-Related Carcinoma, Fanconi Anemia | Not applicable | Recruiting | Masonic Cancer Center, University of Minnesota | 170 | 2022-07-08 | 2026-07-22 |
| Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions Metformin, Biopsy - Erythroplakia, Leukoplakia | Phase 1 | Terminated | Thomas Jefferson University | 4 | 2022-05-04 | 2025-05-15 |
| Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study Cisplatin, Intensity-Modulated Proton Therapy, Quality-of-Life Assessment - Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary | Phase 2 | Active not recruiting | Mayo Clinic | 174 | 2022-02-16 | 2026-07-16 |
| Customized 3D Printed Oral Stents During Head and Neck Radiotherapy Best Practice, Medical Device Usage and Evaluation - Head and Neck Carcinoma, Malignant Parotid Gland Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 88 | 2021-05-26 | 2026-10-06 |
| Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment Medical Device Usage and Evaluation, Consultation, Exercise Intervention - Head and Neck Carcinoma, Hypopharyngeal Carcinoma | Not applicable | Completed | Thomas Jefferson University | 12 | 2021-03-28 | 2025-05-22 |
| Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer Celecoxib, Placebo, Quality-of-Life Assessment - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Terminated | University of Utah | 13 | 2019-11-27 | 2025-02-12 |
| Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab - Oral Cavity Carcinoma, Oral Intraepithelial Neoplasia | Phase 2 | Completed | M.D. Anderson Cancer Center | 15 | 2017-06-14 | 2025-10-23 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion Laboratory Biomarker Analysis, Metformin Hydrochloride - Erythroplakia, Hyperplasia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 26 | 2016-06-10 | 2026-06-26 |
| Behavior Changing Intervention for Smokeless Tobacco and Betel Quid Use in Adolescents BCI for SLT and BQ Use in Adolescents: A CRT - Oral Cavity Carcinoma | Not applicable | Completed | Dow University of Health Sciences | 2200 | 2016-05-01 | 2019-07-17 |
| Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Long-term Follow-up - Anal Carcinoma, Cervical Carcinoma | Active not recruiting | National Cancer Institute (NCI) | 8670 | 2009-03-30 | 2026-08-28 | |
| Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer physiotherapy - Oral Cavity Carcinoma, Oropharyngeal Cancer | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 97 | 2008-12-01 | 2013-07-02 |
Mouth Neoplasms (18) · Oropharyngeal Neoplasms (7) · Hypopharyngeal Neoplasms (6) · Laryngeal Neoplasms (6) · Head and Neck Neoplasms (4) · Paranasal Sinus Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Erythroplasia (2) · Hyperthermia (2) · Maxillary Sinus Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Mucinous (1) · Adrenocortical Carcinoma (1) · Anus Neoplasms (1) · Bile Duct Neoplasms (1)
Mouth Diseases (18) · Neoplasms (18) · Neoplasms by Site (18) · Stomatognathic Diseases (18) · Head and Neck Neoplasms (14) · Otorhinolaryngologic Diseases (9) · Otorhinolaryngologic Neoplasms (9) · Pharyngeal Diseases (9) · Pharyngeal Neoplasms (9) · Pathological Conditions, Signs and Symptoms (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Laryngeal Diseases (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6)
Diathermy (2) · Hyperthermia, Induced (2) · Magnetic Resonance Spectroscopy (2) · Metformin (2) · Radiotherapy (2) · Specimen Handling (2) · Surgical Procedures, Operative (2) · pembrolizumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (1) · Behavior Therapy (1) · Biopsy (1) · CTLA-4 Antigen (1) · Celecoxib (1) · Cisplatin (1)
National Cancer Institute (NCI) (3) · Erasmus Medical Center (2) · M.D. Anderson Cancer Center (2) · Thomas Jefferson University (2) · Aveta Biomics, Inc. (1) · Centre Francois Baclesse (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dow University of Health Sciences (1) · Masonic Cancer Center, University of Minnesota (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1) · University of Utah (1) · VLP Therapeutics (1)
United States (11) · Netherlands (2) · Canada (1) · Costa Rica (1) · Denmark (1) · France (1) · Guam (1) · Pakistan (1)
Michiel Kroesen, MD, Dr. (2) · Aimee Kreimer (1) · Anna Lee (1) · Fred M Baik, MD (1) · Kashif Sahfique, PhD (1) · Renata Ferrarotto (1) · Richard Cannon, MD (1) · Ryan N Hellums (1) · Sandip P Patel (1) · Scott C. Lester, M.D. (1) · Scott M Lippman (1)
PMID 25229260, PMID 30388182, PMID 31969335, PMID 33271093, PMID 33362722, PMID 33882143, PMID 34255745, PMID 34380663, PMID 34716198, PMID 35709811, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 40953868, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
N01CN00031 (1), P30CA023074 (1), P30CA042014 (1), U10CA180888 (1)